Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter AIO phase II trial (LICC)

References

• Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol Off J Eur Soc Med Oncol. 2016;27(8):1386–10. doi:10.1093/annonc/mdw235.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Colon cancer (Version 4). (2018). https://www.nccn.org. Accessed August 1st, 2020.
   Google Scholar
• National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Rectal cancer (Version 3). (2018). https://www.nccn.org. Accessed August 1st, 2020.
   Google Scholar
• de Jong MC, Pulitano C, Ribero D, Strub J, Mentha G, Schulick RD, Choti MA, Aldrighetti L, Capussotti L, Pawlik TM. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg. 2009;250(3):440–448. doi:10.1097/SLA.0b013e3181b4539b.
   PubMed Web of Science ®Google Scholar
• Nordlinger B, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachellier P, Jaeck D, Française de Chirurgie A. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association française de Chirurgie. Cancer. 1996;77(7):1254–1262. doi:10.1002/(SICI)1097-0142(19960401)77:7<1254::AID-CNCR5>3.0.CO;2-I.
   PubMed Web of Science ®Google Scholar
• Fong Y, Cohen AM, Fortner JG, Enker WE, Turnbull AD, Coit DG, Marrero AM, Prasad M, Blumgart LH, Brennan MF. Liver resection for colorectal metastases. J Clin Oncol Off J Am Soc Clin Oncol. 1997;15(3):938–946. doi:10.1200/JCO.1997.15.3.938.
   PubMed Web of Science ®Google Scholar
• Kato T, Yasui K, Hirai T, Kanemitsu Y, Mori T, Sugihara K, Mochizuki H, Yamamoto J. Therapeutic results for hepatic metastasis of colorectal cancer with special reference to effectiveness of hepatectomy: analysis of prognostic factors for 763 cases recorded at 18 institutions. Dis Colon Rectum. 2003;46(10Suppl):S22–31. doi:10.1097/01.DCR.0000089106.71914.00.
   PubMedGoogle Scholar
• Pawlik TM, Scoggins CR, Zorzi D, Abdalla EK, Andres A, Eng C, Curley SA, Loyer EM, Muratore A, Mentha G, et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg. 2005;241(5):715–722. discussion 722-724. doi:10.1097/01.sla.0000160703.75808.7d.
   PubMed Web of Science ®Google Scholar
• Rees M, Tekkis PP, Welsh FKS, O’Rourke T, John TG. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg. 2008;247(1):125–135. doi:10.1097/SLA.0b013e31815aa2c2.
   PubMed Web of Science ®Google Scholar
• Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14(12):1208–1215. doi:10.1016/S1470-2045(13)70447-9.
   PubMed Web of Science ®Google Scholar
• Portier G, Elias D, Bouche O, Rougier P, Bosset J-F, Saric J, Belghiti J, Piedbois P, Guimbaud R, Nordlinger B, et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol Off J Am Soc Clin Oncol. 2006;24(31):4976–4982. doi:10.1200/JCO.2006.06.8353.
   PubMed Web of Science ®Google Scholar
• Folprecht G, Gruenberger T, Bechstein W, Raab H-R, Weitz J, Lordick F, Hartmann JT, Stoehlmacher-Williams J, Lang H, Trarbach T, et al. Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study). Ann Oncol. 2014;25(5):1018–1025. doi:10.1093/annonc/mdu088.
   PubMed Web of Science ®Google Scholar
• Holch JW, Ricard I, Stintzing S, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran S-E, Heintges T, Lerchenmüller C, et al. Relevance of liver-limited disease in metastatic colorectal cancer: subgroup findings of the FIRE-3/AIO KRK0306 trial. Int J Cancer. 2018;142(5):1047–1055. doi:10.1002/ijc.31114.
   PubMed Web of Science ®Google Scholar
• Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet Lond Engl. 2008;371(9617):1007–1016. doi:10.1016/S0140-6736(08)60455-9.
   PubMed Web of Science ®Google Scholar
• Folprecht G, Gruenberger T, Bechstein WO, Raab H-R, Lordick F, Hartmann JT, Lang H, Frilling A, Stoehlmacher J, Weitz J, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. 2010;11(1):38–47. doi:10.1016/S1470-2045(09)70330-4.
   PubMed Web of Science ®Google Scholar
• Suzuki H, Shoda J, Kawamoto T, Shinozaki E, Miyahara N, Hotta S, Iizuka Y, Nakahara A, Tanaka N, Yanaka A, et al. Expression of MUC1 recognized by monoclonal antibody MY.1E12 is a useful biomarker for tumor aggressiveness of advanced colon carcinoma. Clin Exp Metastasis. 2004;21(4):321–329. doi:10.1023/B:CLIN.0000046133.35133.cc.
   PubMed Web of Science ®Google Scholar
• Zhang K, Tang W, Qu X, Guo Q, Inagaki Y, Seyama Y, Abe H, Gai R, Kokudo N, Sugawara Y, et al. KL-6 mucin in metastatic liver cancer tissues from primary colorectal carcinoma. Hepatogastroenterology. 2009;56(93):960–963.
   PubMedGoogle Scholar
• Sangha R, Butts C. L-BLP25: a peptide vaccine strategy in non-small cell lung cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2007;13(15 Pt 2):s4652–4654. doi:10.1158/1078-0432.CCR-07-0213.
   PubMed Web of Science ®Google Scholar
• Zeng Y, Zhang Q, Zhang Y, Lu M, Liu Y, Zheng T, Feng S, Hao M, Shi H, Singh PK. MUC1 predicts colorectal cancer metastasis: a systematic review and meta-analysis of case controlled studies. PloS One. 2015;10(9):e0138049. doi:10.1371/journal.pone.0138049.
   PubMed Web of Science ®Google Scholar
• Butts C, Murray N, Maksymiuk A, Goss G, Marshall E, Soulières D, Cormier Y, Ellis P, Price A, Sawhney R, et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(27):6674–6681. doi:10.1200/JCO.2005.13.011.
   PubMed Web of Science ®Google Scholar
• Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, Nawrocki S, Ciuleanu T-E, Bosquée L, Trigo JM, et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15(1):59–68. doi:10.1016/S1470-2045(13)70510-2.
   PubMed Web of Science ®Google Scholar
• Schimanski CC, Mohler M, Schon M, van Cutsem E, Greil R, Bechstein WO, Hegewisch-Becker S, von Wichert G, Vohringer M, Heike M, et al. LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases–a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial. BMC Cancer. 2012;12(1):144. doi:10.1186/1471-2407-12-144.
   PubMedGoogle Scholar
• Moehler M, Maderer A, Ehrlich A, Foerster F, Schad A, Nickolay T, Ruckes C, Weinmann A, Sivanathan V, Marquardt JU, et al. Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program. BMC Cancer. 2019;19(1):55. doi:10.1186/s12885-018-5223-7.
   PubMedGoogle Scholar
• Remmele W, Stegner HE. [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. Pathol. 1987;8:138–140.
   Google Scholar
• Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230(3):309–318. discussion 318-321. doi:10.1097/00000658-199909000-00004.
   PubMed Web of Science ®Google Scholar
• Scurr M, Pembroke T, Bloom A, Roberts D, Thomson A, Smart K, Bridgeman H, Adams R, Brewster A, Jones R, et al. Low-dose cyclophosphamide induces antitumor T-cell responses, which associate with survival in metastatic colorectal cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2017;23(22):6771–6780. doi:10.1158/1078-0432.CCR-17-0895.
   PubMed Web of Science ®Google Scholar
• Wang Y-J, Fletcher R, Yu J, Zhang L. Immunogenic effects of chemotherapy-induced tumor cell death. Genes Dis. 2018;5(3):194–203. doi:10.1016/j.gendis.2018.05.003.
   PubMed Web of Science ®Google Scholar
• Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, Solary E, Le Cesne A, Zitvogel L, Chauffert B. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother CII. 2007;56(5):641–648. doi:10.1007/s00262-006-0225-8.
   PubMed Web of Science ®Google Scholar
• Kan S, Hazama S, Maeda K, Inoue Y, Homma S, Koido S, Okamoto M, Oka M. Suppressive effects of cyclophosphamide and gemcitabine on regulatory T-cell induction in vitro. Anticancer Res. 2012;32:5363–5369.
   PubMed Web of Science ®Google Scholar
• Allard MA, Adam R, Giuliante F, Lapointe R, Hubert C, Ijzermans JNM, Mirza DF, Elias D, Laurent C, Gruenberger T, et al. Long-term outcomes of patients with 10 or more colorectal liver metastases. Br J Cancer. 2017;117(5):604–611. doi:10.1038/bjc.2017.218.
   PubMed Web of Science ®Google Scholar
• Tranchart H, Chirica M, Faron M, Balladur P, Lefevre LB, Svrcek M, de Gramont A, Tiret E, Paye F. Prognostic impact of positive surgical margins after resection of colorectal cancer liver metastases: reappraisal in the era of modern chemotherapy. World J Surg. 2013;37(11):2647–2654. doi:10.1007/s00268-013-2186-3.
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu YF, Cheng Y, Yi DH, Li P, Song WQ, Fu DZ, Wang X. Prognosis of colorectal cancer with liver metastasis: value of a prognostic index. Braz J Med Biol Res. 2010;43(11):1116–1122. doi:10.1590/S0100-879X2010007500103.
   PubMed Web of Science ®Google Scholar
• Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, Lillemoe KD, Yeo CJ, Cameron JL. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002;235(6):759–766. doi:10.1097/00000658-200206000-00002.
   PubMed Web of Science ®Google Scholar
• Duncan TJ, Watson NFS, Al-Attar AH, Scholefield JH, Durrant LG. The role of MUC1 and MUC3 in the biology and prognosis of colorectal cancer. World J Surg Oncol. 2007;5(1):31. doi:10.1186/1477-7819-5-31.
   PubMedGoogle Scholar
• Baldus SE, Mönig SP, Huxel S, Landsberg S, Hanisch F-G, Engelmann K, Schneider PM, Thiele J, Hölscher AH, Dienes HP. MUC1 and nuclear beta-catenin are coexpressed at the invasion front of colorectal carcinomas and are both correlated with tumor prognosis. Clin Cancer Res Off J Am Assoc Cancer Res. 2004;10(8):2790–2796. doi:10.1158/1078-0432.CCR-03-0163.
   PubMed Web of Science ®Google Scholar
• Baldus SE, Mönig SP, Hanisch F-G, Zirbes TK, Flucke U, Oelert S, Zilkens G, Madejczik B, Thiele J, Schneider PM, et al. Comparative evaluation of the prognostic value of MUC1, MUC2, sialyl-Lewis(a) and sialyl-Lewis(x) antigens in colorectal adenocarcinoma. Histopathology. 2002;40(5):440–449. doi:10.1046/j.1365-2559.2002.01389.x.
   PubMed Web of Science ®Google Scholar
• Khanh DT, Mekata E, Mukaisho K, Sugihara H, Shimizu T, Shiomi H, Murata S, Naka S, Yamamoto H, Endo Y, et al. Transmembrane mucin MUC1 overexpression and its association with CD10+ myeloid cells, transforming growth factor-β1 expression, and tumor budding grade in colorectal cancer. Cancer Sci. 2013;104(7):958–964. doi:10.1111/cas.12170.
   PubMed Web of Science ®Google Scholar
• Lillehoj EP, Lu W, Kiser T, Goldblum SE, Kim KC. MUC1 inhibits cell proliferation by a beta-catenin-dependent mechanism. Biochim Biophys Acta. 2007;1773(7):1028–1038. doi:10.1016/j.bbamcr.2007.04.009.
   PubMed Web of Science ®Google Scholar
• Díaz Del Arco C, Garré P, Molina Roldán E, Lorca V, Cerón Nieto MÁ, Fernández Aceñero MJ. MUC1 expression in colorectal carcinoma: clinicopathological correlation and prognostic significance. Rev Espanola Patol Publicacion Of Soc Espanola Anat Patol Soc Espanola Citol. 2018;51(4):204–209. doi:10.1016/j.patol.2018.03.002.
   PubMedGoogle Scholar
• Betge J, Schneider NI, Harbaum L, Pollheimer MJ, Lindtner RA, Kornprat P, Ebert MP, Langner C. MUC1, MUC2, MUC5AC, and MUC6 in colorectal cancer: expression profiles and clinical significance. Virchows Arch Int J Pathol. 2016;469(3):255–265. doi:10.1007/s00428-016-1970-5.
   PubMed Web of Science ®Google Scholar
• Butts C, Murray RN, Smith CJ, Ellis PM, Jasas K, Maksymiuk A, Goss G, Ely G, Beier F, Soulières D. A multicenter open-label study to assess the safety of a new formulation of BLP25 liposome vaccine in patients with unresectable stage III non-small-cell lung cancer. Clin Lung Cancer. 2010;11(6):391–395. doi:10.3816/CLC.2010.n.101.
   PubMed Web of Science ®Google Scholar
• Butts C, Anderson H, Maksymiuk A, Vergidis D, Soulières D, Cormier Y, Davis M, Marshall E, Falk M, Goss G. Long-term safety of BLP25 liposome vaccine (L-BLP25) in patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC). J Clin Oncol. 2009;27(15_suppl):3055. doi:10.1200/jco.2009.27.15_suppl.3055.
   Web of Science ®Google Scholar
• Cunningham D, Salazar R, Sobrero A, Ducreux MP, Van Cutsem E, Scheithauer W, Tournigand C, Molnar V, Starke M, Baumann M, et al. LBA33Lefitolimod vs standard of care (SOC) for patients with metastatic colorectal cancer (mCRC) responding to first-line standard treatment: results from the randomized phase III IMPALA trial. Ann Oncol. 2019;30(Supplement_5):v868–v869. doi:10.1093/annonc/mdz394.022.
   Google Scholar
• Grothey A, Tabernero J, Arnold D, De Gramont A, Ducreux MP, O’Dwyer PJ, Van Cutsem E, Bosanac I, Srock S, Mancao C, et al. LBA19Fluoropyrimidine (FP) + bevacizumab (BEV) + atezolizumab vs FP/BEV in BRAFwt metastatic colorectal cancer (mCRC): findings from Cohort 2 of MODUL – a multicentre, randomized trial of biomarker-driven maintenance treatment following first-line induction therapy. Ann Oncol. 2018;29(suppl_8): doi:10.1093/annonc/mdy424.020
   Google Scholar